Helixor Mistletoe Therapy

What Is Helixor?

Helixor is a standardised Viscum album preparation produced by Helixor Heilmittel GmbH, a German pharmaceutical company specialising in mistletoe therapy. It is manufactured using an aqueous extraction process — a cold-press method that preserves the natural lectin and viscotoxin content of the mistletoe plant without fermentation.

Three host-tree variants are available: Helixor P (Pinus — pine), Helixor M (Malus — apple), and Helixor A (Abies — fir). The pine preparation is the most widely used and has been studied specifically in lung cancer and respiratory tract malignancies. The apple preparation is used for breast and gynaecological cancers, mirroring the indication of Iscador M.

Helixor is ML-I dominant — its lectin profile is characterised by high concentrations of mistletoe lectin I, which is the most extensively studied lectin in terms of immunomodulatory activity. ML-I stimulates natural killer (NK) cell activity, increases interleukin production, and has demonstrated apoptotic effects on tumour cells in laboratory studies.

Aqueous Extraction vs Fermentation

The key distinction between Helixor and Iscador is the production method. Helixor uses aqueous (cold-press) extraction, which involves pressing the fresh mistletoe plant and filtering the resulting juice to produce a standardised extract. Iscador uses rhythmical fermentation, combining summer and winter plant extracts through a temperature-controlled rotational process.

Proponents of fermentation argue that the process increases biological activity by altering the molecular structure of lectins. Proponents of aqueous extraction argue that cold-press methods better preserve the natural lectin content without denaturation. Head-to-head comparative trials between the two methods are limited, and no definitive clinical superiority has been established for either approach.

Clinical Evidence for Helixor

Helixor has been studied in several randomised controlled trials and observational studies. Key evidence includes studies in lung cancer patients using Helixor P, which demonstrated improvements in quality of life and performance status. A 2020 systematic review by Kienle and Kiene, which included studies across all three major mistletoe preparations, found consistent evidence for quality of life improvements across Iscador, Helixor, and Abnoba preparations.

The Society for Integrative Oncology (SIO) and the European Society for Medical Oncology (ESMO) guidelines reference mistletoe therapy broadly, encompassing all standardised preparations including Helixor. The evidence is strongest for quality of life, fatigue reduction, and chemotherapy tolerance — outcomes that are consistent across preparations.

Administration and Dose Titration

Helixor is administered as a subcutaneous injection three times per week on non-consecutive days. The injection is given into the abdominal skin, rotating sites to prevent skin thickening. Patients are trained to self-administer after an initial consultation.

Dose titration follows the same principle as other mistletoe preparations — guided by the local injection-site reaction. A red wheal of 2–5 cm at the injection site indicates appropriate immune activation. If the reaction is absent, the dose is increased; if excessive (greater than 5 cm or accompanied by systemic symptoms), it is reduced. Dr Kloppenburg provides written dosing instructions and a monitoring protocol with each prescription.